Rosetta Genomics Ltd. announced that one of the nation's clinical reference laboratories has selected RosettaGX Reveala (Reveal) as their molecular test of choice for indeterminate thyroid nodules (ITNs) for their network of more than 150 pathologists across the Southwestern United States, including Texas, Oklahoma, Louisiana, New Mexico, Nevada and Arizona. Reveal is a thyroid microRNA classifier for the classification of ITNs. Following an extensive review of all assays currently available for the classification of ITNs, Reveal was selected as their molecular test of choice based on its ease-of-use and its superior negative predictive value that allows patients who receive a benign Reveal test result to undergo active surveillance instead of surgery. This allows for a substantial reduction in the number of unnecessary surgeries since the vast majority of ITNs are benign and surgery on most of these cases is not necessary.